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Abstract. Psycho-emotional state of rats under thyroid dysfunction. Demchenko . . Spontaneous behavioral 
activity of white rats and concentration of glutamate, glycine and gamma-aminobutyric acid in the neocortex in 
experimental hyper- and hypothyroidism was investigated. It was found that an excess of thyroid hormones was 
accompanied by emotional and anxiolytic effects in terms of reducing duration of grooming by 37% and increasing 
number of transitions and the time spent in the illuminated cross-shaped maze arms (26 % and 35%). Such behavior 
changes occurred against a background of increasing concentrations of GABA by 52 % (p<0,05) in the cortex of 
animals with experimental hyperthyroidism. Perhaps, the psycho-emotional state of the organism is modulated by 
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